INTRODUCTION
============

Clusterin (CLU), a glycoprotein also known as apolipoprotein J, is ubiquitously expressed in various tissues and is upregulated following exposure to cytotoxic stimuli ([@b6-molcell-37-2-178-12]; [@b8-molcell-37-2-178-12]; [@b27-molcell-37-2-178-12]; [@b41-molcell-37-2-178-12]; [@b42-molcell-37-2-178-12]). The single *CLU* gene produces two alternatively spliced isoforms - nuclear CLU (nCLU) and secretory CLU (sCLU) - with differrent subcellular localizations and biological functions ([@b33-molcell-37-2-178-12]; [@b40-molcell-37-2-178-12]; [@b41-molcell-37-2-178-12]; [@b44-molcell-37-2-178-12]). Each isoform contains a unique exon 1 fragment, but both share the remaining sequences (from exon 2 to 9). nCLU is detected as a ∼55 kDa glycosylated protein in the nucleus and induces apoptotic cell death, whereas the mature form of sCLU is a disulfide-linked heterodimeric protein (75--80 kDa) targeted for secretion. In cancer cells, sCLU exerts an anti-apoptotic function and its expression is elevated upon metastasis ([@b1-molcell-37-2-178-12]; [@b3-molcell-37-2-178-12]; [@b17-molcell-37-2-178-12]; [@b36-molcell-37-2-178-12]). However, no definitive mechanism has been proposed to account for the differential expression of these isoforms. Understanding how the expression of these isoforms is regulated may provide new strategies for the diagnosis, prevention, and treatment of cancers.

Recent reports have shown that epigenetic modifications of the *CLU* promoter are involved in tumorigenesis ([@b20-molcell-37-2-178-12]; [@b39-molcell-37-2-178-12]). It has been shown that the *CLU* promoter is methylated in LNCaP and TRAMP C2 cells in association with downregulation of CLU expression ([@b28-molcell-37-2-178-12]). In contrast, the *CLU* promoter is reported to be unmethylated in PC3 and DU145 cells ([@b28-molcell-37-2-178-12]; [@b34-molcell-37-2-178-12]). Epigenetic regulation of the *CLU* gene appears to be important in tumor development and progression, particularly in prostate cancer.

Hypoxia, a characteristic feature of several pathological states, including cancer ([@b37-molcell-37-2-178-12]), induces stabilization of hypoxia-inducible factor-1α (HIF-1α), which transcriptionally activates various genes involved in anaerobic metabolism, angiogenesis, and cell survival ([@b23-molcell-37-2-178-12]). A recent report also showed that CLU is induced by hypoxia in human tendinopathy at both mRNA and protein levels ([@b21-molcell-37-2-178-12]), suggesting that hypoxia may directly regulate the transcription of *CLU* through a hypoxia-induced signaling pathway. Regulation of promoter activity in hypoxia occurs through the interaction of HIF-1α with a hypoxia response element (HRE) ([@b38-molcell-37-2-178-12]). Here, we identified three putative HRE sites (A/GCGTG) in the *CLU* promoter using a bioinformatics analysis and demonstrated that HIF-1α bound to these sites and activated nCLU expression. Moreover, we found that nCLU expression is epigenetically regulated, suggesting that controlling methylation of the *CLU* promoter would be an effective approach for inducing apoptotic cell death and thus might be a good strategy for treating cancers.

MATERIALS AND METHODS
=====================

Cell culture
------------

The human prostate cancer cell lines, PC3M and LNCaP, were obtained from the American Type Culture Collection (USA) and were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 μg/ml streptomycin (HyClone, Thermo, USA). Cells were maintained in a humidified 5% CO~2~ incubator at 37°C. For low oxygen (O~2~) treatment, cells were cultured in a hypoxic incubator (Sanyo Electron Corporation) adjusted to 1% O~2~ for 6, 9, or 24 h.

Cell viability assay
--------------------

Cell viability was measured using the 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. MTT solution (2 mg/ml) was added to each well and incubated with cells at 37°C for 4 h. The resulting formazan crystals were dissolved in dimethyl sulfoxide, and absorbance was measured at 570 nm using a microplate reader (Tecan, Switzerland).

Immunocytochemistry
-------------------

Cells were fixed in 4% formaldehyde and permeabilized with 0.1% Triton X-100 in phosphate-buffered saline (PBS). Fixed cells were stained with primary goat anti-CLU antibody (1:250; Santa Cruz Biotechnology, USA) for 2 h, followed by incubation with Alexa Fluor488-conjugated anti-goat IgG (Invitrogen, USA) in the dark for 1 h at room temperature. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assays were performed using an *in situ* Cell Death Detection Kit (Roche, Germany), according to the manufacturer's protocol. Cells were mounted using ProLong Gold antifade reagent containing the nuclear stain 4′,6-diamidino-2-pheny-lindole (DAPI; Invitrogen, USA).

Immunoblotting
--------------

Cells were homogenized in lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 5 mM EDTA, 1% Nonidet P-40) and Protease Inhibitor Cocktail (Sigma-Aldrich, USA). Cell lysates containing equal amounts of total proteins were electrophoresed and transferred to nitrocellulose membranes. Blots were probed with anti-HIF-1α, anti-vascular endothelial growth factor (VEGF), anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase) antibodies (Cell Signaling, USA); and anti-CLU and anti-β-actin antibodies (Santa Cruz Biotechnology). Immunoreactive antigens were detected using an Enhanced Chemiluminescence Detection Kit (Amersham Bioscience, USA). Images were analyzed using the ImageJ program.

Quantitative polymerase chain reaction
--------------------------------------

Total RNA was extracted using the RNeasy Mini kit (Qiagen, Germany) and converted into cDNA with the Reverse Transcription System (Promega, USA) according to the manufacturer's protocol. Quantitative polymerase chain reaction (PCR) was performed on a LightCycler 480 Real-Time PCR System using Power SYBR Green PCR Master Mix (Roche, Switzerland). Relative mRNA levels were normalized to those of β-actin mRNA. The primers used in these experiments have been described in previous reports ([@b4-molcell-37-2-178-12]; [@b5-molcell-37-2-178-12]; [@b11-molcell-37-2-178-12]).

Plasmid construction
--------------------

The *CLU* upstream promoter region was subcloned by PCR using genomic DNA extracted from PC3M cells as a template. The primers used for PCR were as follows: −806 *Kpn*I forward, 5′-GAT A[GG TAC C]{.ul}GA TTT CCT AAC TGG GAA GGC TC-3′; −480 *Kpn*I forward, 5′-GAT A[GG TAC C]{.ul}CG TTT CAA TAC TTC CTG TGC TCT-3′; −125 *Kpn*I forward, 5′-GAT A[GG TAC C]{.ul}CT TCC AGA AAG CTC CCC T-3′; −76 *Kpn*I forward, 5′-GAT A[GG TAC C]{.ul}AT GCA GGT TTG CAG CCA G-3′; and +51 *Bgl*II reverse, 5′-TCG C[AG ATC T]{.ul}GT CAG CGG CAC CC-3′. The restriction sites are underlined. PCR products were digested with *Kpn*I and *Bgl*II restriction enzymes and inserted into the pGL3 basic vector (Promega). HRE mutants were generated using site-directed mutagenesis. All constructs were confirmed by direct sequencing (Bioneer, Korea).

Luciferase assay
----------------

Cells were transfected using Lipofectamine LTX (Invitrogen), according to the manufacturer's instructions. After 24 h, cells were washed with cold PBS and lysed in lysis buffer provided in the Luciferase Assay System (Promega). Transfection efficiency was normalized using the β-Galactosidase Enzyme Assay System (Promega), and luminescence was measured using a microplate reader (Tecan, Switzerland).

Electrophoretic gel mobility shift assay
----------------------------------------

Electrophoretic mobility shift assays (EMSAs) were performed using a DIG Gel Shift Kit (Roche), as specified by the manufacturer. The sequences of the three oligonucleotide probes containing HREs were as follows: HRE1 probe, 5′-CAT TCT TTG GG[C GTG]{.ul} AGT CAT GCA G-3′ (−95 to −71); HRE2 probe, 5′-CGG GCT AAC CG[C GTG A]{.ul}GA GGG GCT C-3′ (−301 to −277); and HRE3 probe, 5′-ATT AAA CCA AA[C GTG]{.ul} GAT CTG CAA G-3′ (−714 to −690). The *VEGF* promoter probe was used as described previously ([@b4-molcell-37-2-178-12]). The HRE binding site, CGTG, was mutated to TCGG for each probe. For competition assays, unlabeled and mutant probes were added to the reaction mixture prior to addition of the labeled probe. The HIF-1α binding complex was electrophoresed on a 6% native polyacrylamide gel, transferred to a positively charged nylon membrane, and incubated with an alkaline phosphatase-conjugated anti-digoxigen antibody. Associated alkaline phosphatase activity was subsequently detected by incubation with the chemiluminescent substrate CSPD.

Chromatin immunoprecipitation assay
-----------------------------------

Chromatin immunoprecipitation (ChIP) assays were performed as previously described ([@b24-molcell-37-2-178-12]) using anti-HIF-1α antibodies. The following primer pairs were used for quantitative PCR: ChIP HRE1, 5′-CCC AGC CCG GTG CTG CAC CG-3′ (forward) and 5′-GGG CAC TGG GAG GCG CCG TA-3′ (reverse); ChIP HRE2, 5′-TTT AAA TGG GTC AAG AGA AGT GG-3′ (forward) and 5′-CAG TAG GGA AGA GCC TGA ACT C-3′ (reverse); ChIP HRE3, 5′- CTA ACT GGG AAG GCT CAG GGC-3′ (forward) and 5′-ATC TTT TTG GAA CCC AAC CAA GC-3′ (reverse).

Methylation analysis
--------------------

Genomic DNA was obtained using an i-Genomic DNA Extraction Kit (Intron Biotechnology, Korea). Methylation analysis of the *CLU* promoter was performed by detecting restriction enzyme-sensitive sites using a PCR-based protocol, as previously described ([@b39-molcell-37-2-178-12]). Briefly, DNA from prostate cancer cells was digested with the methylation-sen-sitive restriction enzyme, *Ksp*I, which acts on a specific sequence (CCGCGG) located in the *CLU* promoter. Digested genomic DNA was used as the template for PCR. Amplified products were analyzed using gel electrophoresis and ethidium bromide staining, followed by imaging with the Gel Doc EQ System (Bio-Rad Laboratories, USA).

Statistical analysis
--------------------

Results are representative of three independent values presented as means ± standard deviation (SD). Significances of differences were expressed as *P* \< 0.001 (^\*\*\*^), *P* \< 0.005 (^\*\*^), or *P* \< 0.01 (^\*^) compared to controls.

RESULTS
=======

Cobalt chloride induces apoptosis
---------------------------------

To examine whether hypoxic conditions are cytotoxic towards PC3M prostate cancer cells, we treated cells with 200 or 400 μM cobalt chloride (CoCl~2~), a hypoxia-mimetic agent, for 3, 6 or 9 h, and determined cell viability relative to that of untreated cells incubated for the same times. CoCl~2~ induced a concentration- and time-dependent reduction in cell viability, as shown in [Fig. 1A](#f1-molcell-37-2-178-12){ref-type="fig"}. To examine CoCl~2~-induced apoptosis and relate it with CLU expression in these cells, we performed TUNEL assays and immunofluorescence staining for CLU. CoCl~2~-treated cells showed intense nuclear TUNEL staining, which, interestingly, was associated with enhanced nuclear expression of nClu ([Fig. 1B](#f1-molcell-37-2-178-12){ref-type="fig"}).

CoCl~2~ promotes the expression of HIF-1α target genes and nCLU
---------------------------------------------------------------

To further examine whether hypoxic conditions affect CLU expression in PC3M cells, we treated cells with CoCl~2~ and measured CLU mRNA and protein levels. CoCl~2~ treatment is known to stabilize HIF-1α protein and promote expression of its target genes. Using real-time PCR analyses, we confirmed an increase in the mRNA levels of HIF-1α target genes, including VEGF and GAPDH. CoCl~2~ treatment induced a concentration-and time-dependent increase (2-3-fold) in nCLU mRNA levels ([Fig. 2A](#f2-molcell-37-2-178-12){ref-type="fig"}). We also examined changes in the protein levels of HIF-1α and its known target genes, as well as nCLU, by Western blot analysis. As expected, protein levels of HIF-1α, VEGF, and GADH were increased by CoCl~2~ treatment. nCLU, detected as a 55 kDa band, was also increased by CoCl~2~ treatment ([Fig. 2B](#f2-molcell-37-2-178-12){ref-type="fig"}). These results suggest that treatment of PC3M cells with CoCl~2~ reduces cell viability through increased expression of HIF-1α-responsive genes, including nCLU, which is a known pro-apoptotic protein. To demonstrate that HIF-1α is directly responsible for CLU gene expression, we also transiently transfected PC3M cells with a green fluorescent protein (GFP)-tagged HIF-1α expression plasmid. Overexpression of GFP-tagged HIF-1α, confirmed by fluorescence microscopy, induced an increase in the levels of nCLU mRNA and protein ([Figs. 2C and 2D](#f2-molcell-37-2-178-12){ref-type="fig"}), supporting the interpretation that HIF-1α directly promotes the expression of nCLU.

Differential regulation of nCLU expression in PC3M and LNCaP cells following exposure to low O~2~
-------------------------------------------------------------------------------------------------

To monitor transcriptional regulation of nCLU in response to genuine hypoxia, we exposed cells to 1% O~2~ for up to 24 h and analyzed the expression levels of HIF-1α and nCLU by real-time PCR and Western blot analysis ([Fig. 3](#f3-molcell-37-2-178-12){ref-type="fig"}). To assess the role of differential epigenic modification in regulating CLU expression, we compared the two prostate cancer cell lines, PC3M and LNCaP, which differ with respect to *CLU* promoter methylation. In both cell lines, 1% O~2~ maximally induced HIF-1α after 6 h; however, nCLU expression was induced in PC3M, but not in LNCaP cells, at both mRNA ([Fig. 3A](#f3-molcell-37-2-178-12){ref-type="fig"}) and protein levels ([Fig. 3B](#f3-molcell-37-2-178-12){ref-type="fig"}). Moreover, hypoxia induced a more significant decrease in cell viability in PC3M than in LNCaP cells ([Fig. 3C](#f3-molcell-37-2-178-12){ref-type="fig"}). These results suggest that hypoxia induces nCLU expression and subsequent cell death and that this regulation may be epigenetically controlled, as previously reported ([@b28-molcell-37-2-178-12]; [@b34-molcell-37-2-178-12]).

Putative HRE sites identified in the human *CLU* promoter function in the transcriptional regulation of CLU
-----------------------------------------------------------------------------------------------------------

An analysis of the genomic sequences of human *CLU* identified three putative HRE sites in the promoter region ([Fig. 4A](#f4-molcell-37-2-178-12){ref-type="fig"}). Based on the locations of HRE sites, the sequences from −806 to +51 relative to the start site of HIF-1α were cloned into the promoter region of a luciferase reporter plasmid. The functionality of each HRE site was assessed by deleting multiple or individual HRE sites ([Fig. 4B](#f4-molcell-37-2-178-12){ref-type="fig"}). Luciferase activity was determined in the presence or absence of 400 μM CoCl~2~ as well as under conditions of HIF-1α overexpression. The transcriptional activity of constructs containing HRE1, HRE1 and HRE2, or all three HRE sites was significantly increased under hypoxia-mimetic (CoCl~2~ treatment) conditions ([Fig. 4C](#f4-molcell-37-2-178-12){ref-type="fig"}) and with transient HIF-1α overexpression ([Fig. 4D](#f4-molcell-37-2-178-12){ref-type="fig"}). To further confirm the respective activity of the three HRE sites, we generated mutant reporter constructs by site-directed mutagenesis ([Fig. 4E](#f4-molcell-37-2-178-12){ref-type="fig"}). All three HRE mutants exhibited decreased luciferase activity ([Fig. 4F](#f4-molcell-37-2-178-12){ref-type="fig"}), indicating that all HRE sites in the promoter contribute to the transcriptional activation of *CLU*.

The three HRE sites in the *CLU* promoter bind HIF-1α
-----------------------------------------------------

To demonstrate direct binding of HIF-1α to the *CLU* promoter, we performed EMSAs using oligonucleotide probes containing each HRE consensus sequence ([Fig. 5A](#f5-molcell-37-2-178-12){ref-type="fig"}). Binding of HIF-1α to individual HRE sites was detected in reactions containing each labeled probe and nuclear proteins. In competition experiments, gel shifts were suppressed by excess unlabeled wild-type probe, but were not out-competed by mutant probes. Similar results were obtained in positive control EMSAs performed using a nucleotide probe derived from the *VEGF* promoter, which is known to bind HIF-1α. To further confirm the specificity of HIF-1α binding, antibody supershift assays were performed using a HIF-1α antibody. We observed broad and dense bands following the addition of HIF-1α antibody rather than a typical supershifted band. In addition, the HIF-1α antibody failed to alter band intensity at the HRE2 site compared with that at other HRE sites, indicating that this antibody may be not suitable for this assay. Despite these technical limitations, the observations that excess wild-type HRE-containing DNA probes, but not HRE-specific mutant probes, inhibited complex formation between wild-type probes and a nuclear factor in EMSAs, and an anti-HIF-1α antibody generated a supershifted band (albeit atypical) in these assays suggest that the nuclear factor that binds to HRE sites in the *CLU* promoter is HIF-1α.

ChIP assays were further performed to demonstrate direct binding of HIF-1α to endogenous HRE sites in the *CLU* promoter in intact cells. The locations of PCR primers specific to each HRE site are indicated in [Fig. 5B](#f5-molcell-37-2-178-12){ref-type="fig"}. Chromatin immunoprecipitates recruited by the HIF-1α antibody were amplified with each primer sets and their products were quantified ([Fig. 5C](#f5-molcell-37-2-178-12){ref-type="fig"}). Consistent with the direct regulation of *CLU* transcriptional activity by HIF-1α binding, our ChIP data showed that HIF-1α bound to endogenous HRE sites under conditions of CoCl~2~-stimulated hypoxia.

Demethylation of the *CLU* promoter in LNCaP cells enhances nCLU expression and induces apoptotic cell death
------------------------------------------------------------------------------------------------------------

The methylation status of the *CLU* promoter in the prostate cancer cell lines, PC3M, DU145 and LNCaP, was established using a methylation-specific PCR-based approach that detects restriction-sensitive sites. In PC3M and DU145 cell lines, the *CLU* promoter was found to be unmethylated, as evidenced by the presence of a single specific PCR band at the bottom. However, LNCaP cells exhibited two PCR bands, indicative of *CLU* promoter methylation ([Fig. 6A](#f6-molcell-37-2-178-12){ref-type="fig"}). If methylation plays a role in nCLU silencing, demethylation of the *CLU* promoter should result in reactivation of gene expression. Thus, we examined the effect of the demethylating agent, 5-aza-2′-deoxycytidine (AZA), on nCLU expression and subsequent cell death. LNCaP exhibited no nCLU induction in response to treatment with CoCl~2~ or exposure to 1% O~2~ alone and were resistant to the cytotoxic effects of hypoxic stress compared to PC3M cells ([Figs. 3C](#f3-molcell-37-2-178-12){ref-type="fig"} and [6B](#f6-molcell-37-2-178-12){ref-type="fig"}). However, treatment with 3 μM AZA for 3 days followed by treatment with 400 μM CoCl~2~ for 6 h led to enhanced expression of nCLU mRNA ([Fig. 6C](#f6-molcell-37-2-178-12){ref-type="fig"}) and protein ([Fig. 6D](#f6-molcell-37-2-178-12){ref-type="fig"}). Moreover, co-treatment with AZA and CoCl~2~ led to a decrease in the viability of LNCaP cells ([Fig. 6E](#f6-molcell-37-2-178-12){ref-type="fig"}). CLU immunostaining and TUNEL assays demonstrated that LNCaP cells treated with AZA and CoCl~2~ showed a dramatic induction of CLU expression and these CLU-expressing cells overlapped with TUNEL-positive cells ([Fig. 6F](#f6-molcell-37-2-178-12){ref-type="fig"}). Collectively, these data indicate that demethylation of the *CLU* promoter reactivates nCLU expression and promotes apoptotic cell death.

DISCUSSION
==========

The present study showed that nCLU expression is transcriptionally regulated by HIF-1α. Three putative HRE sites in the *CLU* promoter were identified and shown to be functional in luciferase reporter, EMSA, and ChIP assays. Treatment of PC3M cells with 400 μM CoCl~2~ for 6 h was sufficient to stabilize HIF-1α, as previously reported ([@b25-molcell-37-2-178-12]), and enhance expression of its downstream target genes, VEGF and GAPDH ([@b7-molcell-37-2-178-12]; [@b9-molcell-37-2-178-12]; [@b45-molcell-37-2-178-12]). We additionally observed an increase in nCLU expression, providing support for nCLU as a HIF-1α target gene.

CoCl~2~ has been proposed to act by depleting intracellular ascorbate, which, by itself, is sufficient for the inactivation of HIF prolyl hydroxylases and the induction of hypoxia-like stress in cells ([@b35-molcell-37-2-178-12]). It has also been shown that CLU is induced in CoCl~2~-treated, but not in low-oxygenated, human diploid fibroblasts (HDFs), suggesting that distinct cellular components of HDFs may respond differentially to hypoxic stress ([@b26-molcell-37-2-178-12]). Here, we administered short-term, low-dose CoCl~2~ as an HIF-1α-inducing stimulus to avoid the side effect of higher concentrations of CoCl~2~ or longer exposure regimens. For physiological relevance, we further performed experiments under low oxygen (1% O~2~) and established nCLU as a truly hypoxia-responsive gene.

Recent reports have shown that CLU overexpression increases drug sensitivity under hypoxic conditions by increasing apoptosis in colorectal cancer ([@b12-molcell-37-2-178-12]). Diverse cross-talk between CLU and hypoxia suggests that regulation of CLU expression is important for tumor formation and cancer progression, although a direct relationship between the two has not yet been investigated. To our knowledge, this is the first study to identify HRE sites in the *CLU* promoter and demonstrate that they directly bind HIF-1α. Although the full-length promoter spans ∼1,500--2,000 bp of the 5′ regulatory region, we cloned only the sequence from −806 to +51 bp for our luciferase constructs because it contains the clusterin response element (CRE), which is critical for CLU induction, as reported in hepatocellular carcinomas ([@b18-molcell-37-2-178-12]). The functional HRE sites responsible for hypoxia-induced apoptotic cell death were found within this region.

Our study clearly showed the epigenetic regulation of the *CLU* promoter by methylation, as previously described ([@b28-molcell-37-2-178-12]; [@b34-molcell-37-2-178-12]). Since the CpG islands in the *CLU* promoter in PC3M and LNCaP cells have been reported to be differentially methylated, we selected these two cell lines for comparing the levels of nCLU expression and apoptosis. The major difference in methylation is found between −534 and −99 bp within the *CLU* promoter ([@b32-molcell-37-2-178-12]). [@b39-molcell-37-2-178-12] suggested that the methylation position most sensitive to the *KspI* enzyme (−100) is of particular interest, because it is close to the TAATA box and is the target sequence for the transcription factor, AP1. Moreover, HRE1 (−85 to −81) and HRE2 (−291 to −287) sites identified in this study are also in close proximity to this site. Thus, it is reasonable to speculate that DNA sequences capable of being methylated, particularly those proximal to the HRE sites, are critical for epigenetic modification-dependent repression of HIF-1α-mediated transcription, which may be an initial step towards tumorigenesis in early prostate cancers.

In this study, we demonstrated that HIF-1α is a major HRE-binding factor in the *CLU* promoter. However, it should be noted that there are two isoforms of HIF-α - HIF-1α and HIF-2α - that are highly conserved with respect to protein structure; both are also stabilized by hypoxia and bind to the same HRE sites. However, HIF-2α has a distinct, tissue-specific expression pattern and binding partners ([@b19-molcell-37-2-178-12]). HIF-1α is expressed ubiquitously, whereas HIF-2α expression is limited to the endothelium, kidney, lung, heart, and small intestine ([@b43-molcell-37-2-178-12]). In neuroblastomas, HIF-2α is known to be associated with a more aggressive metastatic phenotype ([@b10-molcell-37-2-178-12]). Since our study was performed in prostate cancer cells and focused on the apoptotic function of nCLU at the early stage of cancer, we investigated HIF-1α as the major transcriptional regulator of nCLU expression.

A previous study has reported that von Hippel-Lindau (VHL), a tumor-suppressor protein, regulates CLU expression in a HIF-independent manner in renal carcinomas ([@b22-molcell-37-2-178-12]). However, this study investigated the secretion of sCLU and provided no information about nCLU or methylation status of the promoter. Here, we clearly showed that nCLU expression is HIF-1α dependent and regulated by promoter methylation. As previously shown, the two CLU isoforms are present in various levels in different tissues ([@b2-molcell-37-2-178-12]; [@b30-molcell-37-2-178-12]; [@b31-molcell-37-2-178-12]), and we speculate that each isoform may be differentially expressed according to the abundance of tissue-specific transcription factors and their *cis*-regulatory elements on the promoter as well as by various epigenetic modifications.

We previously proposed that nCLU sequesters the anti-apoptotic Bcl-1 family member, Bcl-xL, *via* its putative BH3 motif and releases bound Bax, thereby promoting apoptosis accompanied by activation of caspase-3 and release of cytochrome c ([@b13-molcell-37-2-178-12]; [@b14-molcell-37-2-178-12]; [@b15-molcell-37-2-178-12]; [@b16-molcell-37-2-178-12]). These results suggest a novel, nCLU-mediated apoptosis mechanism in normal cells. We further propose here that nCLU expression may be silenced in the early stage of prostate cancers *via* promoter methylation, which facilitates the survival of cancer cells ([@b29-molcell-37-2-178-12]; [@b30-molcell-37-2-178-12]). A recent report showed that HIF-1α directly regulates BCL-xL transcription by binding to a HRE in the BCL-xL promoter in prostate cancer cells ([@b4-molcell-37-2-178-12]). This suggests that BCL-xL overexpression is an important mechanism by which HIF-1α protects prostate cancer cells from apoptosis. Thus, our results strongly support the concept that CLU reactivation through relief of methylation-mediated repression would be a good strategy for treating drug resistance.

We conclude that nCLU acts as a tumor-suppressor protein and that the methylation status of the *CLU* promoter could serve as a diagnostic indicator of the early stages of prostate cancer. Moreover, modulating *CLU* promoter methylation could be a promising therapeutic strategy for prostate cancer treatment.

We thank Dr. Jae Yong Park at Gyeongsang National University for providing the HIF-1α expression vector. This research was supported by the Basic Science Research Program through the National Research Foundation (NRF) of Korea (No. 2005-0049415).

Supplementary information is available on the Molecules and Cells website ([www.molcells.org](www.molcells.org)).

![The hypoxia-mimetic compound, CoCl~2~, induces apoptosis in PC3M cells. (A) Viability of PC3M cells in response to CoCl~2~ was measured by MTT assay. PC3M cells were exposed to 0, 200, and 400 μM CoCl~2~ for 3, 6 and 9 h; cell viability is presented relative to controls as a percentage. (B) Immunofluorescence images of PC3M cells showing CLU (green), TUNEL (red), and DAPI (blue) staining. Cells were treated with vehicle or 400 μM CoCl~2~ for 6 h. ^\*^*P* \< 0.01, compared to controls.](molcell-37-2-178-12f1){#f1-molcell-37-2-178-12}

![Treatment with CoCl~2~ and overexpression of HIF-1α induce nCLU expression in PC3M cells. (A, B) PC3M cells were treated with the indicated concentration of CoCl~2~ for the times shown. HIF-1α mRNA (A) and protein (B) were detected by real-time PCR and Western blotting, and quantified. (C, D) PC3M cells were transiently transfected with a GFP-tagged human HIF-1α expression vector. The mRNA (C) and protein (D) were detected by real-time PCR and Western blotting, and quantified. Relative levels were normalized to that of β-actin. ^\*\*\*^*P* \< 0.001, ^\*\*^*P* \< 0.005, ^\*^*P* \< 0.01, compared to controls.](molcell-37-2-178-12f2){#f2-molcell-37-2-178-12}

![Effects of hypoxia on the differential regulation of nCLU expression and cell viability in PC3M and LNCaP cells. PC3M and LNCaP cells were exposed to 1% O~2~ for 6, 9, and 24 h. Expression of HIF-1α and nCLU were analyzed by real-time PCR (A) and Western blotting (B). (C) Cell viability was measured by MTT assay after exposure of cells to 1% O~2~ for 24 h. ^\*\*\*^*P* \< 0.001, ^\*\*^*P* \< 0.005, ^\*^*P* \< 0.01, compared to controls.](molcell-37-2-178-12f3){#f3-molcell-37-2-178-12}

![Putative HRE sites are identified in the *CLU* promoter and mediate luciferase reporter activity. (A) Three potential HRE sites (HRE1, -2, and -3), starting at positions -81, -287 and -700 bp, respectively, in the human *CLU* promoter were identified by sequence analysis. (B) Reporter gene constructs are denoted −806 Luc (−806 to +51), which contains all three HRE sites; −480 Luc (−480 to +51), which contains HRE1 and HRE2; −125 Luc (−125 to +51), which contains HRE1 only; and −76 Luc (−76 to +51), which contains no HREs. (C) HEK 293T cells were transfected with each reporter construct and stimulated with 400 μM CoCl~2~ for 6 h. (D) Cells were co-transfected with each reporter construct and a HIF-1α expression vector. (E, F) Mutant luciferase constructs were designed for each of the three HRE sites (mHRE1, -2, and -3) by site-direct mutagenesis using the −806 Luc reporter plasmid as a backbone. The relative luciferase activity was measured and normalized to the enzymatic activity of β-galactosidase. ^\*\*\*^*P* \< 0.001, ^\*\*^*P* \< 0.005, ^\*^*P* \< 0.01, compared to controls.](molcell-37-2-178-12f4){#f4-molcell-37-2-178-12}

![The three putative HRE sites in the *CLU* promoter bind to HIF-1α. (A) EMSAs were performed using DIG-labeled oligonucleotide probes containing consensus HRE sites. The labeled probe was incubated with ∼25--50 μg of nuclear extract; unlabeled probes were used as competitors. An oligonucleotide probe derived from the *VEGF* promoter was used as a positive control. (B) A schematic drawing of HRE sites and locations of PCR primer pairs for each HRE site-specific ChIP analysis. (C) PC3M cells were treated with 400 μM CoCl~2~ for 6 h, and nuclear fractions were immunoprecipitated with IgG or anti-HIF-1α antibody. Extracted chromatin fragments were analyzed by real-time PCR using the indicated primer sets to amplify sequences corresponding to each HRE site. ^\*\*\*^*P* \< 0.001, ^\*\*^*P* \< 0.005, ^\*^*P* \< 0.01, compared to controls.](molcell-37-2-178-12f5){#f5-molcell-37-2-178-12}

![Demethylation of the *CLU* promoter in LNCaP cells enables CoCl~2~-induced nCLU expression and apoptotic cell death. (A) Genomic DNA from the prostate cell lines, PC3M, DU145 and LNCaP, was digested with the methylation-sensitive restriction enzyme *Ksp*I. Two bands, at 272 and 155 bp, were observed after *Ksp*I treatment in LNCaP cells, whereas only a single band at 155 bp was detected in PC3M and DU145 cells. (B) The viability of LNCaP cells was sustained after treatment with CoCl~2~ treatment compared to that of PC3M cells. (C, D) Treatment with 3 μM AZA for 3 days followed by exposure to 400 μM CoCl~2~ for 6 h enhanced the mRNA and protein levels of nCLU. (E, F) Co-treatment with AZA and CoCl~2~ decreased cell viability (%) and induced strong nCLU and TUNEL staining in LNCaP cells. ^\*\*^*P* \< 0.005, ^\*^*P* \< 0.01, compared to controls.](molcell-37-2-178-12f6){#f6-molcell-37-2-178-12}
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